Uncategorized
Aflibercept may minimize treatment burden in patients with CRVO
CHICAGO — The cystoid macular edema-free interval in patients with non-ischemic central retinal vein occlusion previously treated with ranibizumab or bevacizumab is increased with use of aflibercept, according to a speaker here.Presenting the initial results of the Newton trial, Rahul N. Khurana, MD, told colleagues at Retina Subspecialty Day preceding the American Academy of Ophthalmology meeting that switching to Eylea (aflibercept, Regeneron) may increase the treatment interval in patients with this disease.